Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements in this press release include statements about the potential for MM-111 to provide clinical benefit and to achieve regulatory approval. Forward-looking statements involve substantial risks and uncertainties, and actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT: Media Contacts: Dana Robie Merrimack 617-441-7408 firstname.lastname@example.org Heather Gitlitz Spectrum 202-587-2516 email@example.com